News

Survey Results Show Impact of MS in All Aspects of Life

Multiple sclerosis (MS) affects all aspects of life, from physical and mental health to relationships, and from work and finances to hobbies and holidays, according to results from an online survey conducted by the U.K.’s MS Trust. Most respondents said they wanted more support to manage their fatigue, improve…

Kesimpta Now Reimbursable for Patients in 2 Canadian Provinces

Kesimpta (ofatumumab) is now accessible to eligible Canadians with relapsing-remitting multiple sclerosis (RRMS) through public drug plans in Ontario and Quebec. The treatment has been included as an exceptional medication under both the Ontario Drug Benefit Exceptional Access Program and the Régie de l’assurance maladie du Québec. This…

Trial of Metformin-Clemastine Combo Enrolls First Patient

The first participant has been enrolled in a new clinical trial that is testing whether an antihistamine in combination with a diabetes medication might promote the repair of the myelin sheath in people with multiple sclerosis (MS). The trial’s first participant, Annabelle, was diagnosed with relapsing MS over a…

#AAN2022 – More Patients Given Ublituximab Relapse-free in Trials

More relapsing multiple sclerosis (MS) patients given ublituximab remained relapse-free over the two-year long Phase 3 ULTIMATE clinical trials, compared to those given Aubagio (teriflunomide), new data show. “The prevention of relapses represents an important goal of disease-modifying therapy with the potential for a marked impact on the accumulation of disability,” Lawrence Steinman,…

MSAA Plans In-person and Virtual Events for May

The Multiple Sclerosis Association of America (MSAA) is presenting virtual and in-person ways to support its eighth annual Improving Lives Benefit, which will showcase more than a half-century of efforts for the multiple sclerosis (MS) community. The virtual event, themed “Together at Home,” will be held…

Data Is Lacking on Safety of MS Treatments During Breastfeeding

There is minimal data available on the safety of most disease-modifying therapies for multiple sclerosis (MS) when used during breastfeeding, a new review indicates. The study “Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review,” was published in Frontiers in Neurology. Disease-modifying therapies, or DMTs,…

MSTOP Program in California Cuts DMT Costs and MS Relapse Rates

A program aimed at optimizing the use of highly effective therapies successfully lowered treatment costs and relapse rates among people with multiple sclerosis (MS) in Southern California, according to a study. “Our novel physician-led approach simultaneously reduced MS DMT [disease-modifying therapy] expenditures and the frequency of MS relapses. We…

New Imaging Techniques May Aid MS Diagnosis, Management

Physician-researchers at Cedars-Sinai Medical Center, in California, are developing brain and eye imaging techniques to improve the diagnosis and management of multiple sclerosis (MS). MS is characterized by the progressive loss of myelin, the fatty protective sheath around nerve fibers, in the brain and spinal cord due to abnormal…

Equal DMT Use Found in Norway Despite Socioeconomic Status: Study

People newly diagnosed with multiple sclerosis (MS) in Norway have in recent years received disease-modifying therapies (DMTs) independent of their socioeconomic status, according to a new analysis. These findings do not support previous reports indicating that fewer DMTs are prescribed for the most socially deprived MS patients, the…

Vumerity Added to NHS of England for People With Active RRMS

The National Institute for Health and Care Excellence (NICE) has added oral Vumerity (diroximel fumarate), approved to treat relapsing-remitting multiple sclerosis (RRMS) in the U.K., to the list of medications available through the public health program for England. Because the therapy has been recommended through a fast track appraisal process, Vumerity…

Australia Sets Aside $18M to Support MS Trials, EBV Research

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment

Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…

New Blood Biomarker Technology May Help to Predict MS Activity

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here